Prazitone
Clinical data | |
---|---|
Other names | 5-phenyl-5-(2-piperidylmethyl)barbituric acid |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C16H19N3O3 |
Molar mass | 301.346 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
NY (what is this?) (verify) |
Prazitone (AGN-511) is a barbiturate derivative developed in the 1970s.[1] Unlike most barbiturates, it has little or no sedative effects, instead acting as a non-sedating anxiolytic and antidepressant.[2] The dosage range in humans is around 200–600 mg, although higher doses have been used in trials for the treatment of depression associated with Parkinson's disease.
References
5-HT1AR agonists | |
---|---|
GABAAR PAMs |
|
Gabapentinoids (α2δ VDCC blockers) | |
Antidepressants |
|
Sympatholytics (Antiadrenergics) |
|
Others | |
|
Alcohols |
|
---|---|
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids |
|
Imidazoles | |
Kava constituents |
|
Monoureides |
|
Neuroactive steroids |
|
Nonbenzodiazepines | |
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators |
Simple piperazines (no additional rings) |
|
---|---|
Phenylpiperazines |
|
Benzylpiperazines | |
Diphenylalkylpiperazines (benzhydrylalkylpiperazines) |
|
Pyrimidinylpiperazines |
|
Pyridinylpiperazines |
|
Benzo(iso)thiazolylpiperazines | |
Tricyclics (piperazine attached via side chain) |
|
Others/Uncategorized |
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.